Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients

doi:10.2147/OTT.S257991

	Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients
	Wei, Weitian 1,4,5; Li, Xingliang 3; Song, Mengmeng 2; Wang, Changchun 1,4,5
刊名	ONCOTARGETS AND THERAPY
	2020
卷号	13
关键词	lung cancer gene mutation surgical margin next-generation sequencing
ISSN号	1178-6930
DOI	10.2147/OTT.S257991
通讯作者	Wang, Changchun(ccw7878@163.com)
英文摘要	Objective: To investigate the genetic mutations in both tumor and marginal tissues in patients with non-small cell lung cancer (NSCLC), and to evaluate the potential prognostic value in patients with margins gene positive. Methods: Next-generation sequencing (NGS) technique was used to detect genetic mutation in tumor and marginal tissues of the bronchus in 88 patients with NSCLC. Correlation of genetic mutations with pathology, lymph node metastasis, disease-free survival and overall survival was analyzed. Results: Of the 88 patients, 83 cases (94.3%) had gene mutations in the tumor samples and 12 cases (13.6%) had genetic alterations in their margins. Most of the gene mutations detected were cancer drivers. Six common driver genes between tumor and marginal tissues were identified, including EGFR, TP53, CDKN2A, CTNNB1, BRAF, and NF1. Kaplan-Meier analysis revealed that the median disease-free survival (DFS) was significantly shorter in patients with detectable gene mutations in marginal tissues compared with patients without mutations in margins (30.7 versus 24.4 months, log-rank chi(2) = 4.78, P =0.029). Consistently, a shorter median OS was observed in patients harboring gene mutations in margins compared with patients with no mutations in margins (49.1 versus 32.2 months, log-rank chi(2) = 3.669, P =0.055). Conclusion: These findings identify the presence of oncogenic alterations in microscopically negative margins in NSCLC patients associated with elevated risk of relapse and shorter survival time. Thus, examination of microscopically negative margins by NGS represents a valuable approach to predict the clinical outcome of NSCLC patients.
资助项目	Zhejiang Provincial Natural Science - Mathematical Medicine Association Joint Fund[LSY19H160001] ; Medical and Health of Zhejiang Province Scientific Research Project[2013KYA031]
WOS关键词	POST-RECURRENCE SURVIVAL ; BRONCHIAL MARGINS
WOS研究方向	Biotechnology & Applied Microbiology ; Oncology
语种	英语
出版者	DOVE MEDICAL PRESS LTD
WOS记录号	WOS:000575933700001
资助机构	Zhejiang Provincial Natural Science - Mathematical Medicine Association Joint Fund ; Medical and Health of Zhejiang Province Scientific Research Project
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/104458]
专题	中国科学院合肥物质科学研究院
通讯作者	Wang, Changchun
作者单位	1.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou 310022, Peoples R China 2.Geneplus Beijing Inst, Beijing 102206, Peoples R China 3.Zhejiang Rongjun Hosp, Dept Thorac Dis, Diag & Treatment Ctr, Jiaxing 314000, Zhejiang, Peoples R China 4.Zhejiang Canc Hosp, Dept Thorac Oncol Surg, Hangzhou 310022, Peoples R China 5.Univ Chinese Acad Sci, Dept Thorac Oncol Surg, Canc Hosp, Hangzhou 310022, Peoples R China
推荐引用方式 GB/T 7714	Wei, Weitian,Li, Xingliang,Song, Mengmeng,et al. Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients[J]. ONCOTARGETS AND THERAPY,2020,13.
APA	Wei, Weitian,Li, Xingliang,Song, Mengmeng,&Wang, Changchun.(2020).Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients.ONCOTARGETS AND THERAPY,13.
MLA	Wei, Weitian,et al."Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients".ONCOTARGETS AND THERAPY 13(2020).